Literature DB >> 9918687

Characterization of B lymphocytes rescued from apoptosis by platelet-activating factor.

B J Toledano1, Y Bastien, F Noya, B Mazer.   

Abstract

B lymphocyte development is characterized by deletion via apoptosis of immature cells that are insufficiently stimulated. We have previously demonstrated that crosslinking of the B cell receptor (BCR) using anti-IgM antibodies (alphaIgM) (2 microg/ml) in Ramos B lymphoblastoid cells causes deletion of 30-40% of cells by apoptosis in 24 h. Addition of the potent lipid mediator platelet-activating factor (10(-7) M) to alphaIgM stimulated Ramos cells significantly decreases the number of apoptotic cells as measured by annexin V labeling. We have characterized the phenotype of Ramos cells that have not become apoptotic following BCR stimulation. In these cells, there is a significant decrease in the surface expression of the VLA-4 adhesion molecule (31% of control expression) and surface IgM expression (sIgM) (53% of control expression). Significantly fewer cells co-incubated with platelet-activating factor (PAF) underwent apoptosis, and the remaining cells maintained control levels of VLA-4 (104% of control expression) and sIgM expression (104% of control). All of these protective effects were inhibited by the specific PAF receptor antagonist, WEB 2170. The action of PAF on alphaIgM induced apoptosis was not inhibited by either cycloheximide or cytochalasin B, suggesting that de novo protein synthesis and F-actin polymerization were not implicated in the rescue of Ramos cells by PAF. In contrast, the ability of PAF to maintain sIgM and VLA-4 expression at control levels was inhibited by cycloheximide (7. 5 microg/ml). Cytochalasin B (5 microg/ml) had no effect on sIgM expression but blocked the decrease in VLA-4 expression mediated by alphaIgM. These data indicate that PAF's effect on rescuing and maintaining alphaIgM stimulated Ramos B cells is mediated via at least two pathways. Abrogation of apoptosis does not require de novo protein synthesis, while maintenance of sIgM and VLA-4 expression requires protein synthesis. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918687     DOI: 10.1006/cimm.1998.1410

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  The Ile198Thr and Ala379Val variants of plasmatic PAF-acetylhydrolase impair catalytical activities and are associated with atopy and asthma.

Authors:  S Kruse; X Q Mao; A Heinzmann; S Blattmann; M H Roberts; S Braun; P S Gao; J Forster; J Kuehr; J M Hopkin; T Shirakawa; K A Deichmann
Journal:  Am J Hum Genet       Date:  2000-03-24       Impact factor: 11.025

2.  Induction of B-cell lymphoma by UVB radiation in p53 haploinsufficient mice.

Authors:  Nahum Puebla-Osorio; Yasuko Miyahara; Sreevidya Coimbatore; Alberto Y Limón-Flores; Nasser Kazimi; Stephen E Ullrich; Chengming Zhu
Journal:  BMC Cancer       Date:  2011-01-26       Impact factor: 4.430

3.  Platelet-activating factor antagonists decrease follicular dendritic-cell stimulation of human B lymphocytes.

Authors:  Isaac Halickman; Yolande Bastien; Qianli Zhuang; Monty B Mazer; Baruch Toledano; Bruce D Mazer
Journal:  Allergy Asthma Clin Immunol       Date:  2005-06-15       Impact factor: 3.406

4.  Platelet-activating factor-induced NF-kappaB activation and IL-8 production in intestinal epithelial cells are Bcl10-dependent.

Authors:  Alip Borthakur; Sumit Bhattacharyya; Waddah A Alrefai; Joanne K Tobacman; Krishnamurthy Ramaswamy; Pradeep K Dudeja
Journal:  Inflamm Bowel Dis       Date:  2010-04       Impact factor: 5.325

5.  Correlation of the expression of YY1 and Fas cell surface death receptor with apoptosis of peripheral blood mononuclear cells, and the development of multiple organ dysfunction in children with sepsis.

Authors:  Judith Reséndiz-Martínez; Juan Asbun-Bojalil; Sara Huerta-Yepez; Mario Vega
Journal:  Mol Med Rep       Date:  2017-03-09       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.